• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PEAR

    Pear Therapeutics Inc.

    Subscribe to $PEAR
    $PEAR
    Computer Software: Prepackaged Software
    Technology

    Pear Therapeutics, Inc. engages in developing and commercializing software-based medicines. The company has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurologic conditions. Its products include PearConnect, a patient service center for prescription digital therapeutics; reSET for the treatment of substance use disorder; reSET-O for the treatment of opioid use disorder; and Somryst for the treatment of chronic insomnia. The company was founded in 2013 and is based in Boston, Massachusetts.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: https://peartherapeutics.com

    Recent Analyst Ratings for Pear Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    1/26/2022$5.00Neutral
    B of A Securities
    1/20/2022$11.00Outperform
    Credit Suisse
    1/3/2022$12.00Buy
    BTIG Research
    12/29/2021$13.00Buy
    Citigroup
    12/22/2021$16.00Buy
    Chardan Capital
    12/16/2021Outperform
    Cowen & Co.
    See more ratings

    Pear Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by 5am Partners Iv, Llc

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      4/12/23 4:51:37 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Snow Ellen

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:14:54 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Brenner Erin K.

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:14:18 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by O'Brien Ronan

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:14:04 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Maricich Yuri

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:13:27 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Strandberg Julia

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:13:12 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Guiffre Christopherd T

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:12:48 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Mccann Corey

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:12:24 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4: Wicks Timothy A was granted 52,380 shares

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:12:06 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4: Schlichting Nancy M was granted 66,666 shares

      4 - Pear Therapeutics, Inc. (0001835567) (Issuer)

      2/17/23 4:11:50 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    Pear Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

      MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

      4/3/23 4:05:00 PM ET
      $GLS
      $PEAR
      $SGHT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • Jorge Gomez Joins Moderna as Chief Financial Officer

      CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel."I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee," said Mr. Bancel. "As we grow and scale the company globally, Jorge's experience leading the financial functions of multinational healthcare companies will be an asset to our team. Jorge's passion for sustainabilit

      4/11/22 9:00:00 AM ET
      $CAH
      $MRNA
      $PEAR
      $XRAY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Computer Software: Prepackaged Software

    Pear Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B of A Securities initiated coverage on Pear Therapeutics with a new price target

      B of A Securities initiated coverage of Pear Therapeutics with a rating of Neutral and set a new price target of $5.00

      1/26/22 7:01:40 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Credit Suisse initiated coverage on Pear Therapeutics with a new price target

      Credit Suisse initiated coverage of Pear Therapeutics with a rating of Outperform and set a new price target of $11.00

      1/20/22 7:36:22 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • BTIG Research initiated coverage on Pear Therapeutics with a new price target

      BTIG Research initiated coverage of Pear Therapeutics with a rating of Buy and set a new price target of $12.00

      1/3/22 7:33:46 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Citigroup initiated coverage on Pear Therapeutics with a new price target

      Citigroup initiated coverage of Pear Therapeutics with a rating of Buy and set a new price target of $13.00

      12/29/21 7:22:35 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Chardan Capital initiated coverage on Pear Therapeutics with a new price target

      Chardan Capital initiated coverage of Pear Therapeutics with a rating of Buy and set a new price target of $16.00

      12/22/21 7:43:03 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Cowen & Co. initiated coverage on Pear Therapeutics

      Cowen & Co. initiated coverage of Pear Therapeutics with a rating of Outperform

      12/16/21 8:05:50 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    Pear Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13D/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      4/28/23 4:07:09 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13D/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      4/12/23 4:33:35 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13G/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      2/14/23 4:06:28 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13D/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      9/16/22 5:09:42 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13G/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      2/14/22 9:32:01 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Pear Therapeutics Inc. (Amendment)

      SC 13G/A - Pear Therapeutics, Inc. (0001835567) (Subject)

      2/14/22 6:22:48 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    Pear Therapeutics Inc. SEC Filings

    See more
    • SEC Form 25-NSE filed by Pear Therapeutics Inc.

      25-NSE - Pear Therapeutics, Inc. (0001835567) (Subject)

      5/2/23 1:36:49 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Pear Therapeutics, Inc. (0001835567) (Filer)

      4/10/23 4:36:29 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Pear Therapeutics, Inc. (0001835567) (Filer)

      4/7/23 11:32:19 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 10-K filed by Pear Therapeutics Inc.

      10-K - Pear Therapeutics, Inc. (0001835567) (Filer)

      3/31/23 4:01:03 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Pear Therapeutics, Inc. (0001835567) (Filer)

      3/17/23 9:17:55 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events

      8-K - Pear Therapeutics, Inc. (0001835567) (Filer)

      2/24/23 4:05:21 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form S-8 filed by Pear Therapeutics Inc.

      S-8 - Pear Therapeutics, Inc. (0001835567) (Filer)

      2/9/23 4:42:40 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form EFFECT filed by Pear Therapeutics Inc.

      EFFECT - Pear Therapeutics, Inc. (0001835567) (Filer)

      1/12/23 12:15:14 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 424B5 filed by Pear Therapeutics Inc.

      424B5 - Pear Therapeutics, Inc. (0001835567) (Filer)

      1/10/23 4:20:29 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 424B3 filed by Pear Therapeutics Inc.

      424B3 - Pear Therapeutics, Inc. (0001835567) (Filer)

      1/4/23 4:19:43 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    Pear Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Pear Therapeutics Reports Third Quarter 2022 Results

      Grew revenue 24% quarter-over-quarter to $4.1 million Expanded patient access with new state and commercial payors Expanded real-world evidence with new peer reviewed publication Reduced quarter-over-quarter operating expenses and cut expected 2023 operating expenses Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its third quarter ended September 30, 2022. "Pear is making strong and steady progress toward our mission of making PDTs mainstream medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "

      11/14/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022

      Pear Therapeutics, Inc. (the "Company") (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its third quarter 2022 financial results after the close of market on Monday, November 14, 2022. Management will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss the Company's financial and business highlights. To access the live conference call or webcast, participants should register online at https://investors.peartherapeutics.com/news-events/events-presentations. To avoid delays, we encourage participants to register fifteen minutes ahead of the

      10/31/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Reports Second Quarter 2022 Results

      20% quarter-over-quarter revenue growth to $3.3 million Recent real-world health economic data for all three of Pear's commercial products show cost-savings1-3 Recent commercial formulary additions for reSET® and reSET-O® Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for its second quarter ended June 30, 2022. "Pear continues to make significant progress in introducing PDTs as an innovative class of medicine," said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. "We believe our evidence generation strategy is de

      8/11/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics to Issue Second Quarter 2022 Financial Results on Thursday, August 11, 2022

      Pear Therapeutics, Inc. (the "Company") (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its second quarter 2022 financial results after the close of market on Thursday, August 11, 2022. Management will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss the Company's financial and business highlights. To access the live conference call or webcast, participants should register online at https://investors.peartherapeutics.com/news-events/events-presentations. To avoid delays, we encourage participants to register fifteen minutes ahead of the

      7/28/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Reports First Quarter 2022 Financial Results

      108% quarter-over-quarter revenue growth to $2.7 million >9,200 total prescriptions in the first quarter for Pear's three FDA-authorized products Expanded patient access with state payors in Michigan and Oklahoma CMS issued new HCPCS code Pear's first 12-month and 24-month real-world health economic data presented at ISPOR Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported financial results for its first quarter ended March 31, 2022. "Our momentum in 2021 continued into 2022 with strong revenue and prescription volume growth in the first quarter," said Corey

      5/16/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics to Issue First Quarter 2022 Financial Results on Monday, May 16, 2022

      Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the company will issue its first quarter 2022 financial results after the close of market on Monday, May 16, 2022. The company will hold its investor conference call and webcast at 4:30 p.m. ET on the same day to discuss its financial and business highlights. To access the live conference call via telephone, please dial (877) 814-6630 (U.S. callers) or (409) 216-0625 (international callers) and provide passcode 6975673. A live webcast will also be available in the Investors section of the company's website at www.

      5/2/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

      $4.2 million total revenue for the full year 2021 2021 highlights include Current Procedural Terminology (CPT) codes for prescribers, first state Medicaid coverage decision, two major PBM formulary additions, more than 30 organizations providing access, and 9-month HEOR data published Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today reported financial results for its fourth quarter and full year 2021 ended December 31, 2021. Fourth Quarter 2021 Financial Results Pear's total revenue for the fourth quarter of 2021 was $1.3 million, compared with $34 thousand for the fou

      3/28/22 4:02:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on March 28, 2022 at 4:30 p.m. Eastern Time

      Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host a conference call and webcast at 4:30 p.m. ET on Monday, March 28, 2022, to discuss its financial and operating results for the fourth quarter and full year of 2021. To access the live conference call via telephone, please dial (877) 814-6630 (U.S. callers) or (409) 216-0625 (international callers) and provide passcode 8586341. A live webcast will also be available in the Investors section of the company's website at www.peartherapeutics.com. A replay of the webcast will be available in the Investors

      3/14/22 4:05:00 PM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Announces the Acquisition of Two Assets Addressing a Comprehensive Spectrum of Depression Conditions

      Pear Therapeutics announces the acquisition and license of two digital therapeutic assets designed to treat patients with a range of depression symptoms Pear is developing a prescription digital therapeutic (PDT) candidate that may be developed for use alone or in combination with pharmacotherapy to treat patients across a continuum of depression subtypes and severities Pear intends to incorporate both newly acquired and licensed assets into Pear's depression candidate, which will require clinical evaluation, and if promising, would then be evaluated in a potential pivotal clinical trial to support FDA submission Depression represents one of the largest areas of unmet medical need

      12/16/21 8:00:00 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology

    Pear Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process

      Pear Therapeutics, Inc. (NASDAQ:PEAR) ("the Company"), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the Company and its wholly owned subsidiary, Pear Therapeutics (US), Inc. (collectively, the "Debtors") each voluntarily filed for protection under chapter 11 ("Chapter 11") of the U.S. Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") and they intend to pursue a sale of the business or assets under section 363 of the Bankruptcy Code. Prior to the filing of the Chapter 11 cases, the Debtors evaluated a wide ra

      4/7/23 11:30:00 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

      MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

      4/3/23 4:05:00 PM ET
      $GLS
      $PEAR
      $SGHT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • 5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science

      SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade. REZZAYO was developed by Cidara Therapeutics, Inc. (NASDAQ:CDTX), a company seeded and then supported by 5AM Ventures through its Series A and Series B rounds. 5AM's Scott Rocklage served as chair of the board of directors from the company's inception in 2012 through 2019. "Su

      3/23/23 10:19:01 AM ET
      $CDTX
      $ELVN
      $IMPL
      $PEAR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Computer Software: Prepackaged Software
    • Pear Therapeutics Announces Process Exploring Strategic Alternatives

      Pear Therapeutics, Inc. (NASDAQ:PEAR) ("the Company"), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it is engaged in a process to explore strategic alternatives to maximize shareholder value. The Company has engaged MTS Health Partners, L.P. to act as the Company's exclusive financial advisor to assist in evaluating potential alternatives. MTS Health Partners is a leading boutique investment bank that provides strategic and financial advice to the healthcare industry. As part of its process, Pear is exploring the potential for an acquisition, company sale, merger, divestiture of assets, licensing

      3/17/23 9:15:00 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference

      Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the 43rd Annual Cowen Healthcare Conference being held March 6-8, 2023 in Boston. Corey McCann, M.D., Ph.D., President and CEO, will represent the Company in an analyst-led fireside chat on Monday, March 6 at 9:10 a.m. Eastern Time. A live audio webcast can be accessed by clicking here and will be made available in the Investors section of Pear's website at www.peartherapeutics.com. A replay of the webcast will be available on Pear's website for up to 30 days following the live presentat

      2/27/23 8:00:00 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

      Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14 - 16, 2023 in Snowbird, UT. Pear management will participate virtually in 1x1 meetings at the conference. BTIG hosted events are intended for prospective and existing BTIG clients only. To request a meeting with Pear management, please contact your BTIG representative to express interest. About Pear Therapeutics Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the p

      2/2/23 8:00:00 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders

      BrightView expands its initiative with reSET® and reSET-O® to patients across Kentucky, Ohio, Delaware, Massachusetts, and Virginia Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today the expansion of its collaboration with BrightView Health, an addiction treatment provider that offers evidence-based, outpatient addiction treatment programs. This initiative is designed to provide eligible adults suffering from substance use disorder (SUD) and opioid use disorder (OUD) access to reSET® and reSET-O®. BrightView, an innovative and patient-focused leader in SUD and OUD tr

      1/26/23 8:00:00 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

      Pear's prescription digital therapeutics (PDTs), reSET® and reSET-O®, are included on the January 2023 Florida Medicaid Preferred Drug List (PDL), effective January 1, 2023 Florida Medicaid is covering reSET® and reSET-O® for the treatment of substance use disorder and opioid use disorder, respectively, giving Medicaid patients in Florida access to innovative FDA-authorized addiction treatments via their mobile devices Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the inclusion of its PDTs reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug

      1/18/23 8:00:00 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • Pear Therapeutics to Participate in Citi's BioTech C-Suite Virtual Fireside Chat Series

      Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Citi's BioTech C-Suite Virtual Fireside Chat Series on Tuesday, January 24 at 11:00 a.m. ET. Corey McCann, M.D., Ph.D., President and CEO, will participate in the Citi analyst-hosted fireside chat to discuss Pear's progress on market access. Citi hosted events are intended for prospective and existing Citi clients only. To listen to the live event, please contact your Citi representative with interest. About Pear Therapeutics Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR,

      1/17/23 8:00:00 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology
    • California Department of Health Care Services Awards Contract to Pear Therapeutics to Support the Recovery Incentives Program

      The California Department of Health Care Services (DHCS) selected Pear Therapeutics to track and distribute incentives for the groundbreaking Recovery Incentives: California's Contingency Management Program, to treat Medi-Cal members with stimulant use disorder DHCS intends to use the pilot as a basis for informing the design and implementation of a statewide contingency management benefit through the Drug Medi-Cal Organized Delivery System, pending budgetary and statutory authority The California Department of Health Care Services (DHCS) has selected Pear Therapeutics, Inc. (NASDAQ:PEAR), a leader in developing and commercializing software-based medicines, to support the implementat

      1/12/23 8:00:00 AM ET
      $PEAR
      Computer Software: Prepackaged Software
      Technology